Nine Monthly Results Results Snapshot
Figures in Cr
Consolidate Nine Monthly Results
Dec'25
Dec'24
Net Sales
474.31
284.04
Other Operating Income
0.00
0.00
Total Operating income
474.31
284.04
Raw Material Cost
112.42
70.70
Purchase of Finished goods
76.42
60.76
(Increase) / Decrease In Stocks
-3.39
-8.22
Employee Cost
81.94
45.74
Power Cost
0.00
0.00
Manufacturing Expenses
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
Other Expenses
69.23
44.80
Total Expenditure (Excl Depreciation)
336.62
213.78
Operating Profit (PBDIT) excl Other Income
137.69
70.26
Other Income
12.54
7.50
Operating Profit (PBDIT)
150.23
77.76
Interest
16.57
16.25
Exceptional Items
0.00
0.00
Gross Profit (PBDT)
133.66
61.51
Depreciation
21.95
11.61
Profit Before Tax
111.71
49.90
Tax
26.84
9.52
Provisions and contingencies
0.00
0.00
Profit After Tax
84.87
40.38
Extraordinary Items
0.00
0.00
Prior Period Expenses
0.00
0.00
Other Adjustments
0.00
0.00
Net Profit
84.87
40.38
Share in Profit of Associates
0.00
0.00
Minority Interest
2.74
-1.15
Other related items
0.00
0.00
Consolidated Net Profit
83.77
40.73
Equity Capital
46.05
46.05
Face Value
10.0
10.0
Reserves
0.00
0.00
Diluted Earnings per share
7.29
5.04
Operating Profit Margin (Excl OI)
29.03%
24.74%
Gross Profit Margin
28.18%
21.66%
PAT Margin
17.89%
14.22%
Public Share Holdings (%)
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
Nine Monthly Analysis Highlights
Net Sales
YoY Growth in nine months ended Dec 2025 is 98.28%
Standalone Net Profit
YoY Growth in nine months ended Dec 2025 is 601.19%
Operating Profit (PBDIT) excl Other Income
YoY Growth in nine months ended Dec 2025 is 87.69%
Interest
YoY Growth in nine months ended Dec 2025 is 22.06%
Operating Profit Margin (Excl OI)
YoY Growth in nine months ended Dec 2025 has improved from Dec 2024
Compare Nine Monthly Results Of Senores Pharma. With
Figures in Cr
Consolidate Nine Monthly Results
Change(INR)
Change(%)
Net Sales
474.31
1,182.21
-707.90
-59.88%
Other Operating Income
0.00
0.00
0.00
Total Operating income
474.31
1,182.21
-707.90
-59.88%
Raw Material Cost
112.42
744.23
-631.81
-84.89%
Purchase of Finished goods
76.42
25.75
50.67
196.78%
(Increase) / Decrease In Stocks
-3.39
-13.84
10.45
75.51%
Employee Cost
81.94
124.59
-42.65
-34.23%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
69.23
128.13
-58.90
-45.97%
Total Expenditure (Excl Depreciation)
336.62
1,008.86
-672.24
-66.63%
Operating Profit (PBDIT) excl Other Income
137.69
173.35
-35.66
-20.57%
Other Income
12.54
10.33
2.21
21.39%
Operating Profit (PBDIT)
150.23
183.68
-33.45
-18.21%
Interest
16.57
12.31
4.26
34.61%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
133.66
171.37
-37.71
-22.01%
Depreciation
21.95
33.79
-11.84
-35.04%
Profit Before Tax
111.71
137.59
-25.88
-18.81%
Tax
26.84
34.76
-7.92
-22.78%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
84.87
102.84
-17.97
-17.47%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
84.87
102.84
-17.97
-17.47%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
2.74
0.00
2.74
Other related items
0.00
0.00
0.00
Consolidated Net Profit
83.77
102.84
-19.07
-18.54%
Equity Capital
46.05
57.23
-11.18
-19.54%
Face Value
10.00
10.00
0.00
Reserves
0.00
0.00
0.00
Gross Profit Margin
28.18%
14.50%
0.00
13.68%
PAT Margin
17.89%
8.70%
0.00
9.19%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Nine Monthly - Net Sales
Net Sales 52.94 Cr
in Dec 2025Figures in Cr
Nine Monthly - Standalone Net Profit
Standalone Net Profit 11.78 Cr
in Dec 2025Figures in Cr
Nine Monthly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -0.56 Cr
in Dec 2025Figures in Cr
Nine Monthly - Interest
Interest 5.09 Cr
in Dec 2025Figures in Cr
Nine Monthly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -0.67%
in Dec 2025Figures in %
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
